Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most mechanism and risk statements for grapefruit juice with LIPITOR are supported (CYP3A4 inhibition, increased atorvastatin plasma concentrations, and increased myopathy risk with larger quantities). Several specific assertions (potency, explicit rhabdomyolysis wording for grapefruit, interaction breadth including grapefruit seed extract, specific timing advice, and “significantly” increased side effects) are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Grapefruit juice can interact with Lipitor (atorvastatin).
Supported by 7.2 Grapefruit Juice.
Grapefruit juice inhibits CYP3A4.
7.2 states components inhibit CYP 3A4.
CYP3A4 metabolizes Lipitor.
Not explicitly stated in the provided excerpts; label excerpt 7.2 supports the role of CYP3A4 inhibition rather than confirming metabolism by CYP3A4 in this text.
Consuming grapefruit juice can increase Lipitor concentration in the bloodstream.
7.2 states grapefruit juice can increase plasma concentrations of atorvastatin.
Even moderate grapefruit consumption can increase the risk of side effects in patients taking Lipitor.
Partially supported: 17.1 and 7.2 discuss increased myopathy risk with larger quantities (>1 liter and especially >1.2 L/day), but 'moderate' is not defined in the provided label excerpts.
The FDA warns against drinking large quantities of grapefruit juice or eating grapefruit seed extract while taking Lipitor due to increased risk of muscle injury.
Only the 'large quantities' concept is supported (17.1, 7.1/7.2 excerpt). 'Grapefruit seed extract' is not supported by the provided excerpts.
Patients taking Lipitor should closely monitor their muscle symptoms and report any changes to their doctor promptly.
17.1 advises patients starting therapy to report promptly unexplained muscle pain, tenderness, or weakness; also discusses increased risk.
Unsupported Statements
CYP3A4 metabolizes Lipitor.
The provided label excerpts do not explicitly state that CYP3A4 metabolizes atorvastatin.
Inhibiting CYP3A4 reduces the body's ability to break down Lipitor.
The excerpts state CYP3A4 inhibition can increase plasma concentrations, but do not explicitly state 'reduces the body's ability to break down'.
Increased Lipitor concentration can enhance its potency.
Not stated in the provided excerpts.
Consuming grapefruit juice with Lipitor can significantly increase the risk of side effects such as myopathy (muscle weakness).
Label excerpts support increased myopathy risk with larger grapefruit quantities but do not use 'significantly' nor list side effects beyond advising reporting muscle symptoms.
The FDA warns against ... eating grapefruit seed extract ... while taking Lipitor
Grapefruit seed extract is not mentioned in the provided label excerpts.
Patients should avoid grapefruit or grapefruit products.
The provided excerpts do not contain an explicit instruction to 'avoid grapefruit or grapefruit products' (they discuss increased risk with larger quantities).
To minimize potential side effects, patients should take their Lipitor dose at least two hours before or after consuming grapefruit or grapefruit products.
No dosing-timing instruction relative to grapefruit is provided in the excerpts.
Contradictions
Important Omissions
Exact label-anchored thresholds: grapefruit effects are described for 'larger quantities (>1 liter)' in 17.1 and 'especially with excessive grapefruit juice consumption (>1.2 liters per day)' in 7.2.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Core concept (increased plasma concentrations via CYP3A4 inhibition and increased myopathy risk with higher grapefruit juice consumption) is supported, but several over-specific claims (seed extract, avoidance language, timing of dosing, and explicit rhabdomyolysis 'significant' risk) are not supported by the provided label excerpts, which could lead to miscalibrated risk expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Several specific claims are not supported by the provided label excerpts (grapefruit seed extract, exact avoidance directive, two-hour dosing separation, and potency enhancement; also rhabdomyolysis framed directly for grapefruit).
Suggested Improvement
Limit statements to the label excerpts: grapefruit juice components inhibit CYP3A4 and can increase atorvastatin plasma concentrations (especially with excessive intake) and increase risk of myopathy, with patients advised to report unexplained muscle pain, tenderness, or weakness. Avoid adding unsupported details (seed extract, dosing timing, 'potency', 'significantly', and explicit rhabdomyolysis attribution) unless present in the supplied labeling.